WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407133
Description: DMH25 is a novel covalent and potent mTOR inhibitor, which shows in vivo antitumor activity against triple-negative breast cancer cells. ation. DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
MedKoo Cat#: 407133
Chemical Formula: C15H8Br3NO3
Exact Mass: 486.80543
Molecular Weight: 489.94
Elemental Analysis: C, 36.77; H, 1.65; Br, 48.93; N, 2.86; O, 9.80
DMH25 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: DMH25; DMH-25; DMH 25.
IUPAC/Chemical Name: 6,8-dibromo-2-(4-bromophenyl)-3-nitro-2H-chromene
InChi Key: CYEGQBKPPSAVKF-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H8Br3NO3/c16-10-3-1-8(2-4-10)15-13(19(20)21)6-9-5-11(17)7-12(18)14(9)22-15/h1-7,15H
SMILES Code: O=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
The following data is based on the product molecular weight 489.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, Weghe PV, Legembre P. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. J Med Chem. 2015 Aug 14. [Epub ahead of print] PubMed PMID: 26237138.